title: Oral pemphigus: long term behaviour and clinical response to treatment with deflazacort in sixteen cases.
abstract: Systemic corticosteroids remain the mainstay of therapy for pemphigus. Their use has transformed what was almost invariably a fatal illness into one whose mortality is now below 10%. Unfortunately, the high doses and prolonged administration of corticosteroids that are often needed to control the disease result in numerous side effects, many of which are serious or even life-threatening. Sixteen patients affected by oral pemphigus vulgaris were retrospectively examined to illustrate the natural course of the disease and to describe the efficacy of the treatment we utilised. Deflazacort, used with azathioprine, is the steroid of first choice in our therapeutic protocols, while cyclophosphamide and methylprednisolone "pulse therapy" are reserved for cases unresponsive to high doses of oral corticosteroids. In addition, the literature on oral pemphigus vulgaris was reviewed with respect to clinical history, signs and symptoms, management, and treatment outcome.
authors.affiliation: Department of Odontostomatology and Maxillofacial Surgery, University of Naples Federico II, School of Dentistry, Italy.
authors.forename: M D
authors.initials: MD
authors.lastname: Mignogna
authors.forename: L
authors.initials: L
authors.lastname: Lo Muzio
authors.forename: R E
authors.initials: RE
authors.lastname: Mignogna
authors.forename: R
authors.initials: R
authors.lastname: Carbone
authors.forename: E
authors.initials: E
authors.lastname: Ruoppo
authors.forename: E
authors.initials: E
authors.lastname: Bucci
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001379:Azathioprine / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D009059:Mouth Diseases / Q000188:drug therapy* / Q000503:physiopathology; D010392:Pemphigus / Q000188:drug therapy* / Q000503:physiopathology; D011282:Pregnenediones / Q000008:administration & dosage / Q000627:therapeutic use*; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D011282:Pregnenediones; D003520:Cyclophosphamide; C021988:deflazacort; D001379:Azathioprine; D008775:Methylprednisolone